pioglitazone has been researched along with Graves Disease in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 7.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
| "Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 3.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, A | 3 |
| Ferrari, SM | 3 |
| Fallahi, P | 3 |
| Frascerra, S | 2 |
| Santini, E | 1 |
| Franceschini, SS | 2 |
| Ferrannini, E | 3 |
| Piaggi, S | 1 |
| Paolicchi, A | 1 |
| Salvi, M | 1 |
| Pupilli, C | 1 |
| Mancusi, C | 1 |
| Metelli, MR | 1 |
| Orlando, C | 1 |
| Starkey, K | 1 |
| Heufelder, A | 1 |
| Baker, G | 1 |
| Joba, W | 1 |
| Evans, M | 1 |
| Davies, S | 1 |
| Ludgate, M | 1 |
4 other studies available for pioglitazone and Graves Disease
| Article | Year |
|---|---|
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; En | 2009 |
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Topics: Adipocytes; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chemokine CXCL10; Femal | 2011 |
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
Topics: Adult; Chemokine CXCL11; Chemokine CXCL9; Cytokines; Female; Fenofibrate; Gemfibrozil; Graves Diseas | 2010 |
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
Topics: Adipocytes; Adipose Tissue; Anilides; Cell Differentiation; Cells, Cultured; Contraindications; Grav | 2003 |